Published in Lab Business Week, July 22nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Actavis.
Report 1: Actavis announces that it has withdrawn its interest to acquire the generics division of Merck KGaA.
Actavis has performed extensive due diligence on the division and identified significant potential synergies with Actavis operations. However, the Board of Actavis considers that at the price levels that Actavis understands are being offered for the division by other bidders, the transaction would not produce value for Actavis' shareholders and therefore...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.